Wegener Granulomatosis



  • A disease characterized by granulomatous vasculitis involving multiple organs
  • The characteristic triad of involvement includes the upper airway (e.g., otitis, sinusitis, nasal mucosa), lungs, and kidneys.
  • Other organ systems involved include the skin, joints, and nervous system (peripheral/central).
  • As the condition progresses untreated, upper airway erosions, necrotic pulmonary nodules, and renal failure are common.
  • Without treatment, mortality rate is high. With treatment, survival rate is ~75–90% at 5 years.
  • System(s) affected: upper airways (sinusitis, otitis); cardiovascular; gastrointestinal; nervous; pulmonary; renal/urologic; skin/exocrine
  • Synonym(s): antibodies to neutrophilic cytoplasmic antigens (ANCA)-associated vasculitis (to include patients with Wegener and microscopic polyangiitis); granulomatosis with polyangiitis (recommended to replace Wegener as diagnostic term)



  • ~0.4 to 1.2/100,000 persons per year and possibly increasing over the past decade
  • Mean age of onset is the mid-40s, but the disease has been described in all age groups.
  • Predominant sex: male > female (3:2)

3/100,000 persons

Etiology and Pathophysiology

  • Unknown etiology
  • Autoimmune phenomena and immune-complex deposition in arterial walls are implicated, and the activation of neutrophils by bacteria or other infectious agents may be important as well.
    • Role of antibodies directed against neutrophils is currently being investigated.
  • A specific triggering infectious agent has not been identified.

Increased presence in HLA-B8 and HLA-DR2, more recently increase in HLA-DP and genetic variants involved in α1-antitrypsin and protease-3 (1)

There's more to see -- the rest of this topic is available only to subscribers.